SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma (“Aptar”), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar’s Unit Dose System (UDS) for the treatment of opioid overdose.
News Ticker
- [ December 9, 2023 ] Product Release Coordinator- QA Pharmaceutical / Biotech – Full Time Days – Grifols – Los Angeles, CA Los Angeles Biotech Jobs
- [ December 8, 2023 ] “Frozen” Composer Christophe Beck and Kristen Bell Reunite at Education Through Music-Los Angeles Gala Los Angeles Biotech News
- [ December 8, 2023 ] Medical Lab Scientist – Techsara solutions Inc – Mission Viejo, CA Los Angeles Biotech Jobs
- [ December 8, 2023 ] City of Hope Doctors and Scientists Present Innovative Research at Largest Gathering on Breast Cancer Research Los Angeles Biotech News
- [ December 8, 2023 ] UCLA researchers lay groundwork to study effects of maternal diabetes on fetal metabolism and development Featured News
Copyright © 2023 Biotech Networks, LLC
